Connect to other sites within the UBM Medica Network
The AACR and ACCC elect new leaders. Read more about the latest accolades and appointments in the cancer care community.
Researchers identify regulatory protein domains that contribute to tumor cell survival and cancer progression
The p90 ribosomal S6 kinase protein contributes to tumor cell proliferation and survival, the genetic disease Carney complex, and cardiac hypertrophy.
Chemo Added to Surgery Ups OS in Gastric Cancer
Patients who receive chemotherapy after surgery for gastric cancer have a higher rate of survival compared to those patients who have surgery alone.
Gemcitabine Sensitizes Invasive Bladder Tumors to Radiation
Adding gemcitabine (Gemzar) to concurrent radiotherapy and cisplatinum in invasive bladder cancer could preserve the organ even when the tumor has invaded the muscle.
Taxane analog shows ‘unequivocal benefit’ in prostate mets
Cabazitaxel, an investigational taxane, significantly extended survival among prostate cancer patients whose disease had progressed despite hormone therapy.
Eli Lilly joins SNM imaging network
Eli Lilly has joined SNM’s Clinical Trials Network, a collaborative effort designed to address the need for validated imaging biomarkers for streamlining the development and registration of investigational therapeutics.
Blood count test may predict prognosis in leukemia
A multi-institutional group of researchers have zeroed in on a more accurate way to decipher treatment outcomes in young leukemia patients using information from a simple complete blood count test.
Children with acute lymphoblastic leukemia gain little by participating in clinical trials
Parents and their children need to understand that advancing science does not always go hand-in-hand with a direct benefit to the patients.
Brain cancer cells dodge conventional Rx
Typically glioblastoma patients are dead within 15 months of diagnosis, no matter how complete and well-planned their therapy.
Whole-body MRI finds breast cancer metastases earlier
Whole-body MRI should be the go-to imaging modality for detecting bone metastases in asymptomatic patients.
Diffusion-weighted MRI looks to add new biomarker for oncologic imaging
The technique provides a new and continuously evolving tool in oncologic imaging for lesion detection, characterization, and therapy assessment.
Palliative Rx for prostate ca wins OK from FDA
Trelstar (22.5 mg triptorelin pamoate) has received FDA marketing approval as a twice-yearly intramuscular gonadotropin-releasing hormone (GnRH) agonist.
FDA simplifies patient access to investigational drugs
Rules balance access to promising new therapies against the need to protect patient safety.
NCI declares state of crisis in trials
An NCI report concluded that our clinical trial system is nearing a “state of crisis.” This seems like a case of new report, same conclusion.
What are the Ongoing Therapeutic Challenges in Recurrent Squamous Cell Cancer of the Head and Neck?
A medical oncologist, a radiation oncologist, and a surgeon share pearls and pitfalls in their specialized approaches to managing recurrent disease.
H&N imaging gains new radiotracers
PET paired with a variety of radiotracers offers insights into the metabolic, DNA, and protein pathways.
Trial aims to shave years off cancer drug development
The I-SPY 2 breast cancer trial features a novel design of uninterrupted enrollment and patient stratification using biomarkers in order to target therapy.
Global cost-sharing programs for pricey drugs fall short
Survey results indicate patient access schemes in the UK and the U.S. need refinement.
State breast cancer screening programs struggle financially
There’s no shortage of controversy when it comes to mammography-based breast cancer screening.
Daley breast center opens its doors
Opening of the Maggie Daley Center for Women’s Cancer Care at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Multigene assays influence treatment decisions in low-risk breast cancer patients
Tests carry a significant price tag, but reduction in chemotherapy use is potentially cost-saving.
A health insurer actually poses the big question
In today’s contentious debate over how to best deliver cost-effective, value-added healthcare, insurers have become the villain du jour, taking a backseat only to Wall Street fat cats.
International cancer diagnosis, treatment varies widely
Coverage in most countries is universal, but limited resources can sometimes hinder how much coverage a person can expect.